Illuminating Pathways for Disease Research

• Broadcast Date: Wednesday, March 7, 2012
• Time: 1:00 pm EST, 10:00 am PST

REGISTRATION IS FREE

AVAILABLE ON DEMAND

Integration of DNA and RNA sequencing, proteomic, and metabolomic techniques to discover biomarkers of disease processes has advanced rapidly. Recent published examples of pathway-driven multi-omics integration show how these types of analyses can transform understanding of disease biology, identify novel biomarkers, and provide mechanistic insights.

Unlike the full genome, the transcriptome varies with external environmental conditions and includes all mRNA transcripts in the cell, reflecting only actively expressed genes at any given time, and under a particular set of conditions. Therefore, transcriptome analysis, integrated with proteomics and metabolomics can yield valuable information about drug responses, drug resistance, diagnostic markers, and fundamental disease pathways.

In this webinar, presenters will discuss integration of metabolomic and transcriptomic datasets to overcome gaps in knowledge of how existing TB drugs work, coupled global protein expression and transcriptomic analyses to identify drug response biomarkers for use in clinical trials, and integration of proteomic and metabolomic technologies to discover novel biomarkers for disease diagnosis.

What you will learn:

• How post- drug treatment or siRNA knockdown transcriptomic and proteomic changes in the human breast epithelial MCF10 were characterized to investigate initial pharmacodynamic drug candidate responses.
• How quantitative MS analysis of proteins and small compounds in the serum of ankylosing spondylitis (AS) and healthy control patients, combined with vitamin D metabolomics, provides an integrative view that accelerates the discovery of biomarker candidates useful for the diagnosis and monitoring of this disease.
• How metabolomic and transcriptomic datasets can be integrated to address fundamental mechanisms of drug activity and illuminate pathways though which drugs act to inform drug development.

 

Who Should Attend:

• Drug development scientists
• Mass spectrometrists
• Cellular biochemists
• Protein biochemists
• Molecular biologists
• Microbiologists
• Diagnostics developers
• Infectious disease specialists

Panelists Include

• Benedikt M. Kessler, Ph.D., University Research Lecturer, Ubiquitin Proteolysis Group, University of Oxford
• Kyu Rhee, M.D., Ph.D., Associate Professor of Medicine, Microbiology & Immunology, Division of Infectious Diseases, Weill Cornell Medical College
• Akhilesh Pandey, M.D., Ph.D., Professor, McKusick-Nathans Institute of Genetic Medicine, Departments of Biological Chemistry and Oncology, Johns Hopkins

John Sterling, Editor in Chief, Genetic Engineering & Biotechnology News, will be the host of this webinar. A live Q&A session will follow the presentations, offering you a chance to pose questions to our expert panelists.

AVAILABLE ON DEMAND